AUC-guided Bayesian vancomycin dosing improves targets, renal signal unconfirmed
This pre-post study evaluates whether Bayesian AUC24-guided model-informed precision dosing improves vancomycin target attainment and renal safety in a predominantly non-MRSA critically ill cohort.
Bayesian AUC dosing raised target attainment and cut supratherapeutic levels, but the AKI benefit vanished after adjustment.
Vancomycin is crucial for treating gram-positive infections but can cause acute kidney injury (AKI); optimizing dosing may improve safety. Model-informed AUC-based dosing reduced AKI incidence from 27.8% to 14%, and increased target attainment to 70.2% from 55.1%. The study suggests that AUC24-guided dosing can enhance vancomycin safety and efficacy, warranting broader implementation despite limited MRSA prevalence. AUC24-based vancomycin dosing improves safety and target attainment in critically ill patients.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Gundlach L, Kunkel M, Scherf-Clavel O, Surat G
Citation:Gundlach L, Kunkel M, Scherf-Clavel O, et al. Model-informed AUC-guided dosing for parenteral vancomycin in critically ill patients: impact on target attainment and renal safety - a pre-post intervention study. BMC pharmacology & toxicology. 2026;27(1). doi:10.1186/s40360-026-01224-x